Antihemophilic component (AHF) infusion is utilized to treat and forestall genuine draining scenes in patients with a draining issue called hemophilia A. The draining scene might be identified with a harm (injury) or a surgical technique. AHF is a protein that is created normally in the body. It helps the blood structure clusters to quit draining and keeps draining issues from happening as frequently.

Hemophilia A, likewise called established hemophilia, is a condition where the body does not make enough AHF. On the off chance that you don’t have enough AHF and you get to be harmed, your blood won’t frame clumps legitimately. You may seep into and harm your muscles and joints. AHF infusion is given to expand the levels of AHF in the blood.

Submit your review

Create your own review

Average rating:  
 0 reviews
  • Advate, Eloctate, Helixate FS, Hemofil-M, Hyate:C, Koate DVI, Kogenate FS, Monarc-M, Monoclate-P, Obizur, Xyntha
  • Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

    Check with your doctor immediately if any of the following side effects occur:

    More common
    Less common or rare
    Changes in facial skin color
    fast or irregular breathing
    puffiness or swelling of the eyelids or around the eyes
    sensation of burning, warmth, heat, numbness, tightness, or tingling
    skin rash, hives, or itching
    tightness in the chest
    troubled breathing
    unusual tiredness or weakness
    Incidence not known
    Bluish color of the fingernails, lips, skin, palms, or nail beds
    blurred vision
    chest pain or discomfort
    deep or fast breathing with dizziness
    difficult or labored breathing
    difficulty with swallowing
    dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
    fast, pounding, or irregular heartbeat or pulse
    noisy breathing
    numbness of the feet, hands, and around the mouth
    puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
    slow or irregular heartbeat
    swelling of the face, throat, or tongue
    unusual tiredness or weakness
    Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

    More common
    Less common
    Burning, stinging, or swelling at the place of injection
    dizziness or lightheadedness
    dry mouth or bad taste in the mouth
    lack or loss of strength
    redness of the face
    Change in taste
    loss of taste
    Incidence not known
    Abdominal or stomach pain
    feeling of warmth
    increased sweating
    muscle or bone pain
    redness of the eye
    redness of the face, neck, arms, and occasionally, upper chest
    redness of the skin
    trouble seeing
  • Although dosage must be individualized according to the needs of the patient (weight, severity of hemorrhage, presence of inhibitors), the following general dosages are suggested: Number of AHF I.U. required = (body weight (in kg) x desired Factor VIII increase (% normal)) x 0.5 Dosage necessary to maintain the therapeutic plasma level bases on bleeding episode: Minor hemorrhage (superficial, early hemorrhages, hemorrhages into joints): Therapeutically necessary plasma level of FVIII activity is 20% to 40% of normal, repeated every 12 to 24 hours as necessary until resolved. (At least 1 day, depending upon the severity of the bleeding episode.) Moderate (bleeding into muscles, mild head trauma, bleeding into the oral cavity): Therapeutically necessary plasma level of FVIII activity is 30% to 60% of normal, repeated every 12 to 24 hours for 3-4 days or until adequate local hemostasis is achieved. Major (gastrointestinal bleeding, intracranial, intraabdominal or intrathoracic bleeding, fractures): Therapeutically necessary plasma level of FVIII activity is 60% to 100 % of normal, repeated every 8 to 24 hours until bleeding is resolved, resolved, or in the case of surgery, until adequate local hemostasis and wound healing are achieved.